Search Results - "Kokkorakis, Michail"

Impact of Solute Carrier Transporters in Glioma Pathology: A Comprehensive Review by Anagnostakis, Filippos, Kokkorakis, Michail, Markouli, Mariam, Piperi, Christina

“…Solute carriers (SLCs) are essential for brain physiology and homeostasis due to their role in transporting necessary substances across cell membranes. There…”
Get full text

Signatures and Discriminative Abilities of Multi-Omics between States of Cognitive Decline by Anagnostakis, Filippos, Kokkorakis, Michail, Walker, Keenan A, Davatzikos, Christos

“…Dementia poses a substantial global health challenge, warranting an exploration of its intricate pathophysiological mechanisms and potential intervention…”
Get full text

From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need by Kokkorakis, Michail, Boutari, Chrysoula, Katsiki, Niki, Mantzoros, Christos S.

Get full text

The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation by Stefanakis, Konstantinos, Kokkorakis, Michail, Mantzoros, Christos S.

“…Similar to bariatric surgery, incretin receptor agonists have revolutionized the treatment of obesity, achieving up to 15–25 % weight loss in many patients,…”
Get full text

Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery by Kokkorakis, Michail, Katsarou, Angeliki, Katsiki, Niki, Mantzoros, Christos S.

“…The 21st century is characterized by an increasing incidence and prevalence of obesity and the burden of its associated comorbidities, especially…”
Get full text

Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges by Kokkorakis, Michail, Boutari, Chrysoula, Hill, Michael A., Kotsis, Vasilios, Loomba, Rohit, Sanyal, Arun J., Mantzoros, Christos S.

Get full text

Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies by Kokkorakis, Michail, Muzurović, Emir, Volčanšek, Špela, Chakhtoura, Marlene, Hill, Michael A, Mikhailidis, Dimitri P, Mantzoros, Christos S

“…Steatotic liver disease (SLD) displays a dynamic and complex disease phenotype. Consequently, the metabolic dysfunction-associated steatotic liver disease…”
Get more information

GDF-15 improves the predictive capacity of Steatotic liver disease non-invasive tests for incident morbidity and mortality risk for cardio-renal-metabolic diseases and malignancies by Kokkorakis, Michail, Folkertsma, Pytrik, Forte, José Castela, Wolffenbuttel, Bruce H.R., van Dam, Sipko, Mantzoros, Christos S.

“…Noninvasive tools (NITs) are currently used to stratify the risk of having or developing hepatic steatosis or fibrosis. Their performance and a…”
Get full text

Recent research advances in metabolism, clinical and experimental by Boutari, Chrysoula, Kokkorakis, Michail, Stefanakis, Konstantinos, Valenzuela-Vallejo, Laura, Axarloglou, Evangelos, Volčanšek, Špela, Chakhtoura, Marlene, Mantzoros, Christos S.

Get full text

Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study by Kouvari, Matina, Valenzuela-Vallejo, Laura, Guatibonza-Garcia, Valentina, Polyzos, Stergios A., Deng, Yixiang, Kokkorakis, Michail, Agraz, Melih, Mylonakis, Sophia C., Katsarou, Angeliki, Verrastro, Ornella, Markakis, Georgios, Eslam, Mohammed, Papatheodoridis, Georgios, George, Jacob, Mingrone, Geltrude, Mantzoros, Christos S.

“…Non-invasive tools (NIT) for metabolic-dysfunction associated liver disease (MASLD) screening or diagnosis need to be thoroughly validated using liver…”
Get full text

The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study by Kouvari, Matina, Mylonakis, Sophia C., Katsarou, Angeliki, Valenzuela-Vallejo, Laura, Guatibonza-Garcia, Valentina, Kokkorakis, Michail, Verrastro, Ornella, Angelini, Giulia, Markakis, Georgios, Eslam, Mohammed, George, Jacob, Papatheodoridis, Georgios, Mingrone, Geltrude, Mantzoros, Christos S.

“…A new non-invasive tool (NIT) for non-alcoholic fatty liver disease (NAFLD) proposed in 2022 by the multi-ethnic Dallas Heart Study, i.e. the Dallas Steatosis…”
Get full text

FLASH Proton Radiation Therapy Mitigates Inflammatory and Fibrotic Pathways and Preserves Cardiac Function in a Preclinical Mouse Model of Radiation-Induced Heart Disease by Kim, Kyle, Kim, Michele M., Skoufos, Giorgos, Diffenderfer, Eric S., Motlagh, Seyyedeh Azar Oliaei, Kokkorakis, Michail, Koliaki, Ilektra, Morcos, George, Shoniyozov, Khayrullo, Griffin, Joanna, Hatzigeorgiou, Artemis G., Metz, James M., Lin, Alexander, Feigenberg, Steven J., Cengel, Keith A., Ky, Bonnie, Koumenis, Constantinos, Verginadis, Ioannis I.

“…Studies during the past 9 years suggest that delivering radiation at dose rates exceeding 40 Gy/s, known as “FLASH” radiation therapy, enhances the therapeutic…”
Get full text

Effective questionnaire-based prediction models for type 2 diabetes across several ethnicities: a model development and validation study by Kokkorakis, Michail, Folkertsma, Pytrik, van Dam, Sipko, Sirotin, Nicole, Taheri, Shahrad, Chagoury, Odette, Idaghdour, Youssef, Henning, Robert H., Forte, José Castela, Mantzoros, Christos S., de Vries, Dylan H., Wolffenbuttel, Bruce H.R.

“…Type 2 diabetes disproportionately affects individuals of non-White ethnicity through a complex interaction of multiple factors. Therefore, early disease…”
Get full text